Recently, Leahy et al. issued a ''consensus statement'' in regard to targeting b-cell function in therapy for type 2 diabetes that recommends continued multidisciplinary efforts to realign treatment of type 2 diabetes to preserve b-cell function by early intervention. This might be applicable not only for obese type 2 diabetes in Europe and America, but also for lean type 2 diabetes in Asia. To establish evidence, development of noninvasive measurements of b-cell mass for longitudinal observation during long duration of diabetes is critical. In addition, studies that clarify the development of b-cell dysfunction with regard to both mass reduction and functional impairment are required for the development of novel strategies to preserve b-cell function by treatment of type 2 diabetes. 1 recently issued a consensus statement that recommends targeting b-cell function for therapy in type 2 diabetes. The consensus is based on recent studies showing that declining b-cell function, a pathogenesis of type 2 diabetes, begins early in the disease's natural history, accelerates markedly after reaching a compensatory threshold, drives the progression of the disease and is potentially reversible, particularly in the early stages. They concluded that continued multidisciplinary effort to realign treatment of type 2 diabetes to preserve b-cell function by early intervention is both necessary and important.
In a longitudinal study of obese Pima Indians by Weyer et al.
2
, failure to augment b-cell function to compensate for increased insulin demand as a result of decreased insulin sensitivity, due to weight gain for example, was found to be involved in deterioration of glucose homeostasis in type 2 diabetes. It is important to determine whether or not this pathogenesis is also applicable to lean type 2 diabetes in Asia. Sato et al.
showed, by a cross-sectional study using the oral glucose tolerance test, that b-cells begin to deteriorate during normoglycemia with a minimal elevation of fasting plasma glucose in Japanese subjects. In our previous cross-sectional study, endogenous insulin secretion shown by indices of serum C-peptide immunoreactivity (CPR) levels was negatively correlated with years from diagnosis, suggesting progressive deterioration of b-cell function over several decades of diabetes exposure in Japanese type 2 diabetes 4 . Interestingly, body mass index (BMI) was positively correlated with indices of CPR, suggesting that increased insulin resistance positively affects endogenous insulin secretion, even in lean type 2 diabetes. However, the positive effect of BMI on endogenous insulin secretion is weaker in patients with longer duration of diabetes than in those with shorter duration, suggesting a decrease in the capacity to compensate insulin secretion against insulin resistance by disease duration and that early intervention might be necessary, even in lean type 2 diabetes.
A previous study using streptozotocintreated mini-pigs showed that b-cell function in vivo is closely related to b-cell mass, even when only slightly reduced 5 .
A decrease in b-cell mass in type 2 diabetes compared with that in normal subjects is shown by cross-sectional studies using specimens of autopsies or surgical operations, but longitudinal studies are absent. In a cross-sectional study using specimens derived from autopsies, b-cell mass in individuals showed extreme variability and markedly overlapped in normal subjects and patients with type 2 diabetes, despite the significant average decrease in b-cell mass in type 2 diabetes 6 . These results show that measurement of b-cell mass at one time point in an individual cannot predict progression to type 2 diabetes and that longitudinal observation is necessary. Trials to find useful probes to visualize b-cell mass in vivo continue 7 . Such non-invasive methods, if realized, will be valuable to clarify the relationship between function and mass of b-cells during the natural course of type 2 diabetes (Figure 1) . Indeed, glucose-specific impairment of insulin secretion is characteristic in type 2 diabetes; the insulin response to intravenous administration of arginine is preserved, whereas the insulin response to intravenous administration of glucose is severely impaired in patients with type 2 diabetes 10 . Results from diabetic rodent and human islets show that decreased glucose-stimulated insulin secretion in diabetes is derived, at least in part, from impaired metabolism-secretion coupling in b-cells; impaired glucose metabolism and adenosine triphosphate (ATP) production in b-cells causes a decrease in glucose-stimulated insulin secretion. We propose that ATP production in b-cells is impaired by endogenous overproduction of reactive oxygen species (ROS) and by diminished hyperpolarization of mitochondrial membrane potential as a result of overexpression of uncoupling protein and a nuclear factor 11, 12 . Interestingly, an increase in the intracellular cAMP level by GLP-1 receptor agonist ameliorates impaired ATP production by suppressing endogenous ROS generation in diabetic b-cells, which suggests that incretin therapy might have an important role in recovering impaired metabolismsecretion coupling 11 . Studies to elucidate the mechanism of b-cell dysfunction, including mass reduction and functional impairment, will contribute to establishing novel strategies to preserve b-cell function in treatment of type 2 diabetes. Shimpei Fujimoto*, Nobuya Inagaki Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
